Difference between revisions of "Doxorubicin (Adriamycin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Transplant medications" to "") |
m (→Also known as) |
||
| Line 55: | Line 55: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Generic | + | *'''Code name:''' FI-106 |
| + | *'''Generic names:''' ADM, hydroxydaunorubicin | ||
*'''Brand names:''' | *'''Brand names:''' | ||
{| class="wikitable" style="text-align:center;" | {| class="wikitable" style="text-align:center;" | ||
| Line 64: | Line 65: | ||
|Adriacin | |Adriacin | ||
|Adriamycin | |Adriamycin | ||
| + | |Adriamycine | ||
|Adriblastin | |Adriblastin | ||
|Adriblastina | |Adriblastina | ||
|Adriblastine | |Adriblastine | ||
| + | |- | ||
|Adricept | |Adricept | ||
| − | |||
|Adricin | |Adricin | ||
|Adrim | |Adrim | ||
| Line 76: | Line 78: | ||
|Biorrub | |Biorrub | ||
|Biorubina | |Biorubina | ||
| + | |- | ||
|Cadria | |Cadria | ||
| − | |||
|Carcinocin | |Carcinocin | ||
|Cloridrato DE | |Cloridrato DE | ||
| Line 85: | Line 87: | ||
|Dicladox | |Dicladox | ||
|Dobicin | |Dobicin | ||
| + | |- | ||
|Dobixin | |Dobixin | ||
| − | |||
|Doxo | |Doxo | ||
|Doxobin | |Doxobin | ||
| Line 94: | Line 96: | ||
|Doxolem | |Doxolem | ||
|Doxonolver | |Doxonolver | ||
| + | |- | ||
|Doxor | |Doxor | ||
| − | |||
|Doxorrubicina | |Doxorrubicina | ||
|Doxoruben | |Doxoruben | ||
| Line 103: | Line 105: | ||
|Doxorubin | |Doxorubin | ||
|Doxotec | |Doxotec | ||
| + | |- | ||
|Doxtie | |Doxtie | ||
| − | |||
|Duxocin | |Duxocin | ||
|Evacet | |Evacet | ||
| Line 112: | Line 114: | ||
|Ifadox | |Ifadox | ||
|Kemodoxa | |Kemodoxa | ||
| + | |- | ||
|Lipodox | |Lipodox | ||
| − | |||
|Lyphidox | |Lyphidox | ||
|Myocet | |Myocet | ||
| Line 121: | Line 123: | ||
|Oncodria | |Oncodria | ||
|Onkodox | |Onkodox | ||
| + | |- | ||
|Onkostatil | |Onkostatil | ||
| − | |||
|Pallagicin | |Pallagicin | ||
|Ranxas | |Ranxas | ||
| Line 130: | Line 132: | ||
|Rubex | |Rubex | ||
|Varidoxo | |Varidoxo | ||
| + | |- | ||
|Zodox | |Zodox | ||
|} | |} | ||
Revision as of 03:05, 8 June 2019
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Adult T-cell leukemia/lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Cutaneous basal cell carcinoma
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL/SLL)
- Diffuse large B-cell lymphoma
- Ewing sarcoma
- Follicular lymphoma
- Hepatoblastoma
- Hepatocellular carcinoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Osteosarcoma
- Pancreatic NET
- Peripheral T-cell lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Renal cell carcinoma
- Soft tissue sarcoma
- Small cell lung cancer
- Cutaneous squamous cell carcinoma
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Endometrial cancer
- Vascular sarcoma
- Waldenström macroglobulinemia
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/7/1974: Initial FDA approval
- 5/8/2003: Earliest date with label information at Drugs @ FDA: "Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Also known as
- Code name: FI-106
- Generic names: ADM, hydroxydaunorubicin
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Adriablastina | Adriacept | Adriacin | Adriamycin | Adriamycine | Adriblastin | Adriblastina | Adriblastine |
| Adricept | Adricin | Adrim | Adrimedac | Adrosal | Antraciclin | Biorrub | Biorubina |
| Cadria | Carcinocin | Cloridrato DE | Doxorrubicina Colhidrol | Daxotel | Deldoxin | Dicladox | Dobicin |
| Dobixin | Doxo | Doxobin | Doxo Cell | Doxocris | Doxokebir | Doxolem | Doxonolver |
| Doxor | Doxorrubicina | Doxoruben | Doxorubicina | Doxorubicine | Doxorubicinum | Doxorubin | Doxotec |
| Doxtie | Duxocin | Evacet | Farmiblastina | Fauldoxo | Flavicina | Ifadox | Kemodoxa |
| Lipodox | Lyphidox | Myocet | Nagun | Neoxane | Nuaze | Oncodria | Onkodox |
| Onkostatil | Pallagicin | Ranxas | Rastocin | Ribodoxo | Roxorin | Rubex | Varidoxo |
| Zodox | |||||||
References
Categories:
- Drugs
- Intra-arterial medications
- Intravenous medications
- Intravesical medications
- Vesicant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Adrenocortical carcinoma medications
- Adult T-cell leukemia/lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Chronic lymphocytic leukemia medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Follicular lymphoma medications
- Hepatoblastoma medications
- Hepatocellular carcinoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Pancreatic NET medications
- Peripheral T-cell lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Renal cell carcinoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Thymoma medications
- Transformed lymphoma medications
- Endometrial cancer medications
- Vascular sarcoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 1974
- WHO Essential Cancer Medicine